Holen Sie sich die Stockscreener-App
0.6666
4.16%
0.0266
Handel nachbörslich:
.68
0.0134
+2.01%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DRRX?
Forum
Prognose
Aktiensplit
Durect Corp Aktie (DRRX) Neueste Nachrichten
Allay’s $57.5M extends postsurgical pain relief with ATX-101 - BioWorld MedTech
Jane Street Group LLC Purchases 28,486 Shares of DURECT Co. (NASDAQ:DRRX) - Defense World
Durect Corp stock hits 52-week low at $0.52 amid market challenges - Investing.com Australia
Durect Corp stock hits 52-week low at $0.52 amid market challenges By Investing.com - Investing.com South Africa
Durect says on July 24, Impax Laboratories terminated asset transfer and license agreement dated Jan. 3, 2014 - Reuters
DURECT (NASDAQ:DRRX) Now Covered by Analysts at StockNews.com - Defense World
Durect: Q1 Earnings Snapshot - New Haven Register
DURECT (DRRX) Q1 Revenue Surpasses Estimates, Focuses on Phase 3 Trial Funding | DRRX Stock News - GuruFocus
Durect Corp Q1 2025 Earnings: EPS at -$0.13 Misses Estimate, Rev - GuruFocus
DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update - PR Newswire
DURECT (DRRX) Expected to Announce Quarterly Earnings on Monday - Defense World
Durect Corp stock hits 52-week low at $0.69 amid market challenges By Investing.com - Investing.com South Africa
Durect Corp stock hits 52-week low at $0.69 amid market challenges - Investing.com
Form 8-KCurrent report - ADVFN
DURECT Co. (NASDAQ:DRRX) Sees Large Decline in Short Interest - Defense World
DURECT (NASDAQ:DRRX) Now Covered by StockNews.com - Defense World
StockNews.com Initiates Coverage on DURECT (NASDAQ:DRRX) - Defense World
Durect Corp stock hits 52-week low at $0.7 amid market challenges - Investing.com Canada
DURECT (NASDAQ:DRRX) Coverage Initiated at StockNews.com - Defense World
DURECT Corporation (NASDAQ:DRRX) Q4 2024 Earnings Call Transcript - MSN
Here's Why We're A Bit Worried About DURECT's (NASDAQ:DRRX) Cash Burn Situation - Yahoo Finance
DURECT Corporation’s Earnings Call Highlights Cost Cuts and Breakthrough Potential - TipRanks
Durect Corp Q4 2024 Earnings: EPS of $0.25 Surpasses Estimates, Revenue Falls Short at $0.5 Million - GuruFocus
Durect Corp (DRRX) Q4 2024 Earnings Call Highlights: Strategic Focus Amid Financial Challenges - Yahoo Finance
Durect Corp (DRRX) Q4 2024 Earnings Call Highlights: Strategic F - GuruFocus.com
Durect: Q4 Earnings Snapshot - MySA
Durect reports Q4 cont ops EPS (6c), consensus (2c) - TipRanks
Durect (DRRX) Reports Q4 Loss, Lags Revenue Estimates - MSN
Earnings call transcript: Durect’s Q4 2024 revenue drops as focus shifts to key drug - Investing.com India
DURECT Corp reports results for the quarter ended December 31Earnings Summary - TradingView
DURECT Transforms Business: $17.5M Asset Sale, NEJM Evidence Validates Key Drug Program - Stock Titan
Earnings Scheduled For March 26, 2025 - Benzinga
DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - PR Newswire
What To Expect From Durect Corp (DRRX) Q4 2024 Earnings - GuruFocus
ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
DURECT Corporation to Announce Fourth Quarter and Full Year 2024 - GuruFocus.com
DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update - Quantisnow
2.01%
0.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):